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The utility of HTLV-1 proviral load and integration site
analysis by both a linker mediated PCR assay based on
the Universal VectoretteTM System (Sigma Genosys)
and by high through-put sequencing (HTPS) to assess
the treatment response of four patients with chronic
adult T-cell leukaemia/lymphoma (ATLL) undergoing
first line treatment with zidovudine and interferon alpha
(ZDV/IFN-a) at the molecular level is described. Diagno-
sis of chronic ATLL was according to the Shimoyama
criteria. All patients were Afro-Caribbean, median age 52
years (range 32-63), three were female. Median lympho-
cyte count was 8.2x109/L (range 9-23.9) and HTLV-1
proviral load (PVL) was 73.8% (72.6-276.2). All patients
gave informed consent and treatment was according to
clinic protocol. All patients remain alive with median
overall survival of 64 (27 -106) months. A dominant
clone was detected by vectorette and HTPS in all
patients. Complete haematological response (CHR),
defined as normal white cell count and lymphocyte count
for one month, was observed in all patients within nine
months of starting treatment. Two patients were intoler-
ant of therapy long term and a molecular response was
not observed with persistence of the dominant clones on
vectorette and by HTPS. In the two patients tolerant of
therapy a reduction in HTLV-1 PVL was observed 10-40
months after the CHR but the dominant clone remained
detectable by vectorette for a further 20 months on treat-
ment. Two patients have relapsed off treatment and two
remain in CHR. Following CHR molecular methods
reveal residual disease and predict long-term response.
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